Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer’s dementia

Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer’s dementia
Alzheimers Dement (N Y). 2021 Feb 14;7(1):e12106. doi: 10.1002/trc2.12106. eCollection 2021.ABSTRACTBACKGROUND: A Phase II proof of concept (POC) randomized clinical trial was conducted to evaluate the effects of rasagiline, a monoamine oxidase B (MAO-B) inhibitor approved for Parkinson disease, in mild to moderate Alzheimer's disease (AD). The primary objective was to determine if 1 mg of rasagiline daily for 24 ... read more
Source: PubMedPublished on 2021-02-22By Dawn C Matthews